Background: PEPFAR, national governments, and other stakeholders are investing
unprecedented resources to provide HIV treatment in developing countries. This study …

Background Governments and international donors have partnered to provide free HIV
treatment to over 6 million individuals in low and middle-income countries. Understanding …

Since its inception in 2003, the US President's Emergency Plan for AIDS Relief (PEPFAR)
has been an important driving force behind the global scale-up of HIV care and treatment …

The transition to PEPFAR 2.0 with its focus on country ownership was accompanied by
substantial funding cuts. We describe the impact of this transition on HIV care in a large …

Background Today's uncertain HIV funding landscape threatens to slow progress towards
treatment goals. Understanding the costs of antiretroviral therapy (ART) will be essential for …

Background Little information exists on the impact of highly active antiretroviral therapy
(HAART) on health-care provision in South Africa despite increasing scale-up of access to …

Background Given the size of the HIV epidemic in South Africa and other developing
countries, scaling up antiretroviral treatment (ART) represents one of the key public health …

Background In economic analyses of HIV interventions, South Africa is often used as a case
in point, due to the availability of good epidemiological and programme data and the global …

Great variation was observed in the methods used to estimate cost data across the studies
identified, including range of services, patients covered and outcomes costed. Progress in …

Aim: To estimate the cost-effectiveness ratio of highly-active antiretroviral therapy (HAART)
in Canada. Design: A before-and-after analysis to calculate incremental cost of life year …